| 摘要 |
The subject invention pertains to a novel cell line and the monoclonal antibody produced by the cell line. Advantageously, the novel monoclonal antibody binds specifically with the acute lymphocytic leukemia antigen. Thus, this antibody can be used in the detection of childhood leukemia as well as in therapeutic procedures such as bone marrow purging. The novel monoclonal antibody can also be used to construct hybrid toxin proteins which can selectively seek out and eliminate target cells. |
